Trefoil Peptides in Lung Diseases
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Bispebjerg Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Bispebjerg Hospital
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT00839735
First received: February 6, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study focuses on trefoil family factor (TFF) peptides in sputum in lung diseases. The investigators hypothesize that TFF peptides are upregulated in lung diseases characterized by mucus hypersecretion.
| Condition |
|---|
|
Chronic Obstructive Pulmonary Disease Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Trefoil Peptides in Lung Diseases |
Resource links provided by NLM:
Further study details as provided by Bispebjerg Hospital:
Primary Outcome Measures:
- TFF in sputum [ Time Frame: Monthly ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | February 2009 |
| Estimated Study Completion Date: | May 2010 |
| Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
COPD
Chronic obstructive pulmonary disease
|
| Asthma |
| Healthy controls |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
Subjects with chronic obstruction pulmonary disease (COPD) Subjects with asthma Healthy volunteers
Criteria
Inclusion Criteria:
- Age 18 years or older
- Informed consent
Exclusion Criteria:
- Upper and lower airway infection 2 weeks prior to visit 1
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00839735
Contacts
| Contact: Thomas K Lund, MD PhD | (+45) 35 31 30 69 | tclund@dadlnet.dk |
| Contact: Lars Pedersen, MD PhD | (+45) 35 31 30 69 | lars.pedersen@dadlnet.dk |
Locations
| Denmark | |
| Respiratory and Allergy Research Unit, Department of Respiratory Medicine L, Bispebjerg Hospital | Recruiting |
| Copenhagen, Denmark, 2400 | |
| Contact: Thomas K Lund, MD PhD (+45) 35 31 30 69 tclund@dadlnet.dk | |
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
| Principal Investigator: | Thomas K Lund, MD PhD | Respiratory and Allergy Research Unit |
More Information
No publications provided
| Responsible Party: | Thomas K. Lund (MD PhD) & Lars Pedersen (MD PhD), Respiratory and Allergy Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark |
| ClinicalTrials.gov Identifier: | NCT00839735 History of Changes |
| Other Study ID Numbers: | H-B-2008-120 |
| Study First Received: | February 6, 2009 |
| Last Updated: | February 6, 2009 |
| Health Authority: | Denmark: Ethics Committee Denmark: Danish Dataprotection Agency |
Keywords provided by Bispebjerg Hospital:
|
COPD |
Additional relevant MeSH terms:
|
Asthma Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Bronchial Diseases |
Respiratory Tract Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013